1. Home
  2. NRIX vs SHO Comparison

NRIX vs SHO Comparison

Compare NRIX & SHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc. Common stock

NRIX

Nurix Therapeutics Inc. Common stock

HOLD

Current Price

$19.57

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

SHO

Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

HOLD

Current Price

$9.05

Market Cap

1.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
SHO
Founded
2009
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
NRIX
SHO
Price
$19.57
$9.05
Analyst Decision
Strong Buy
Hold
Analyst Count
13
8
Target Price
$26.08
$9.31
AVG Volume (30 Days)
1.8M
1.9M
Earning Date
01-27-2026
11-07-2025
Dividend Yield
N/A
3.98%
EPS Growth
N/A
N/A
EPS
N/A
0.01
Revenue
$83,687,000.00
$937,930,000.00
Revenue This Year
$58.38
$5.75
Revenue Next Year
N/A
$5.65
P/E Ratio
N/A
$943.40
Revenue Growth
48.32
3.04
52 Week Low
$8.18
$7.45
52 Week High
$22.95
$12.41

Technical Indicators

Market Signals
Indicator
NRIX
SHO
Relative Strength Index (RSI) 70.09 46.31
Support Level $16.02 $8.84
Resistance Level $22.50 $9.48
Average True Range (ATR) 1.33 0.21
MACD 0.32 -0.03
Stochastic Oscillator 72.19 32.81

Price Performance

Historical Comparison
NRIX
SHO

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.

Share on Social Networks: